Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning sign. Researchers analyzing millions of medical records found that people ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Theralase Technologies (TSXV:TLT) has shown in pre-clinical trials that its flagship Rutherrin, when activated by X-Ray, is ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Seeing blood in urine is often the first clue that something is wrong. For many people, noticing this symptom prompts a medical visit that can lead ...

Future financings to progress patented hyperthermic technology aimed at improving chemotherapy therapeutic efficacy, tolerability and treatment outcomes for advanced bladder and peritoneal cancers The ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

The MarketWatch News Department was not involved in the creation of this content. -- Investment led by T&J Meyer Family Foundation, joined by Varia Ventures, NW Angel Fund and other non-institutional ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...